Compare ANAB & SBET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANAB | SBET |
|---|---|---|
| Founded | 2005 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2015 | 2025 |
| Metric | ANAB | SBET |
|---|---|---|
| Price | $47.64 | $6.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $87.25 | $16.63 |
| AVG Volume (30 Days) | 447.0K | ★ 8.2M |
| Earning Date | 11-17-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $234,603,000.00 | $28,055,000.00 |
| Revenue This Year | N/A | $67.70 |
| Revenue Next Year | $69.42 | $57.94 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 157.01 | ★ 666.04 |
| 52 Week Low | $30.27 | $4.46 |
| 52 Week High | $73.30 | $12.58 |
| Indicator | ANAB | SBET |
|---|---|---|
| Relative Strength Index (RSI) | 44.91 | 33.36 |
| Support Level | $44.38 | $6.05 |
| Resistance Level | $51.94 | $8.26 |
| Average True Range (ATR) | 2.27 | 0.41 |
| MACD | 0.25 | -0.15 |
| Stochastic Oscillator | 44.55 | 6.54 |
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Sharplink Inc is one of those publicly traded companies to adopt ETH as its primary treasury reserve asset. This move reflects the Company's commitment to align corporate treasury with the future of programmable finance, digital capital markets, and decentralized infrastructure. The Company also operates an online affiliate marketing company that delivers different fan activation solutions to its sportsbook and online casino gaming partners. The company operates in two reportable segments: ETH Treasury Management and Affiliate Marketing. The majority of its revenue is generated from the ETH Treasury Management. Geographically, the company operates in the United States and the rest of the world.